Alzheimer's Disease Trial, Recruiting NCT06147999 Sponsor: First Institute of All Medicines Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT06147999
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must meet the conditions required for approval into the study.
  • You must be 18 years old or older and be willing to stay at a hotel during the study.
  • You must have a caregiver who is willing to support your full involvement in the study and can help you complete all study surveys.
  • You must be able to give your consent to participate, or your caregiver can help you do this.
  • You must have an official diagnosis of a brain disorder from a doctor.
  • You must be able to complete all parts of the study from start to finish.
  • You must be fluent in English, or your caregiver must be able to fully translate for you.
  • If you are a woman who could become pregnant, you must provide the results of a pregnancy test before joining.

Who may not be able to join:

  • People with an untreated mental illness that could affect their ability to take part in the study (this will be decided by the caregiver or a medical expert on the study team).
  • People who depend on a ventilator (a machine that helps them breathe).
  • People who have a deep brain stimulator, pacemaker, or any other electronic device implanted in their body.
  • People with other serious health conditions that could interfere with the study, such as severe lung disease, uncontrolled seizures, active or ongoing infections, severe diabetes, kidney failure, or a terminal prognosis (confirm with trial site).
  • People who are currently taking part in another clinical trial involving a drug or medical device.
  • People who currently have an active infectious disease, such as COVID-19.
  • Women who are pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
First Institute of All Medicines
Registry
ClinicalTrials.gov
Start date
8 November 2023
Est. completion
8 November 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Overall Life Quality impacted by Biophoton Therapy; Cognitive Capacity impacted by Biophoton Therapy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov